Moderna’s mRNA Flu Vaccine Approved by FDA for Two Age Groups in Landmark Vote
The Food and Drug Administration’s vaccine advisory panel has approved Moderna’s new flu vaccine, mFlusiva (mRNA-1010), for older adults. The committee overwhelmingly backed the vaccine for two age brackets: adults aged 50 to 64 and those 65 years and older. Both votes were 9-0 in favor of approving the mRNA-based jab. During a daylong meeting,…